Abstracts non-coverage decision. Of the positive decisions, 22 were associated with an economic evaluation that estimated the medical intervention to be dominant (costs less and more effective than the alternative), 8 with an incremental cost-effectiveness ratio (ICER) of less than $50,000, 8 with an ICER greater than $50,000 but less than $100,000, and 8 with an ICER greater than $100,000 (2008 USD). In four of the positive coverage decisions the intervention was dominated (costs more and was less effective than the alternative). Of the non-coverage decisions, 3 interventions were estimated to be dominant, 6 were associated with an ICER less than $30,000, one with an ICER of approximately $200,000, and four were dominated. Fourteen decision memos cited or discussed cost-effectiveness information. CONCLUSIONS: CMS is covering a number of interventions that do not appear to be cost-effective by traditional standards. While we identifi ed several instances where cost-effectiveness evidence was cited in NCDs, we found no clear evidence of an implicit constant fi xed cost-effectiveness threshold. OBJECTIVES: To examine the out of pocket spending on psychotropic medications by elderly Medicare benefi ciaries before and after the implementation of Medicare Part D. METHODS: The effect of Part D was measured using 2005-2006 pharmacy claims data from one of the largest retail pharmacy chains in the United States. The psychotropic medications examined in this study included antidepressants, antipsychotics benzodiazepines and barbiturates. In addition to evaluating overall out of pocket burden in 2005 and 2006, the study examined out of pocket burden among Medicare-Medicaid dual eligible benefi ciaries, non-dual Part D enrollees, and those who did not enroll in Medicare Part D. The out of pocket burden was calculated as a percentage of total pharmacy reimbursement involving elderly persons 65 years or older. RESULTS: The proportion of out of pocket expenditures in total pharmacy reimbursement dropped 7.62% (from 40.43% to 32.81%) for antidepressants, 6.24% for antipsychotics (from 27.82% to 21.58%), but increased 12.15% for benzodiazepines (from 62.64% to 74.79%), and 9% (from 71.96% to 80.56%) for barbiturates. Dual eligible benefi ciaries were the group most severely affected by the policy change. For dual eligible benefi ciaries who were on any of the four drug categories, their yearly out of pocket expense increased extensively. The most dramatic change was observed in dual eligibles using benzodiazepines. Their out of pocket expenditure increased by around 12 folds from 2005 to 2006. Non-dual Part D enrollees benefi ted the most from the new drug policy. The most signifi cant cost saving was found in non-dual Part D enrollees who were on antidepressants (from 62.23% to 32.97%) and antipsychotics (from 55.24% to 38.30%). CONCLUSIONS: The implementation of Part D was associated with reduced out of pocket psychotropic prescription burden on non-dual Part D enrollees, however, out-of -pocket burden on the dual eligible benefi ciaries severely increased.
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MS1 ASSESSMENT OF PREFERENCE AND SATISFACTION WITH A WEEKLY ORAL TABLET VERSUS A 6-MONTH SUBCUTANEOUS INJECTION FOR THE TREATMENT OF OSTEOPOROSIS
Kendler DL 1 , Gold DT 2 , Horne R 3 , Borenstein J 4 , Varon SF 4 , Man HS 4 , Siddhanti S 4 , Satram-Hoang S 4 , Macarios D 4 , Bone HG 5 1 Clinical Research Centre, Vancouver, BC, Canada, 2 Duke University Center for the Study of Aging and Human Development, Durham, NC, USA, 3 The School of Pharmacy, University of London, London, UK, 4 Amgen Inc, Thousand Oaks, CA, USA, 5 Michigan Bone and Mineral Clinic, Detroit, MI, USA OBJECTIVES: We compared patient preference and satisfaction between two osteoporosis medications: alendronate (ALN 70 mg tablets) taken orally once weekly (QW) and denosumab (DMAb 60 mg; investigational agent) injected subcutaneously (SC) every 6 months (Q6M). METHODS: Preference and satisfaction were evaluated as part of a phase 3, double-blind, double-dummy study to determine the effects of transitioning subjects from ALN to DMAb. Postmenopausal women 55 with a lumbar spine or total hip T-score 2.0 and 4.0 who were receiving ALN therapy for 6 months were eligible. After a 1-month ALN run-in phase, subjects were randomized to treatment with continued ALN QW placebo injection SC Q6M or DMAb SC Q6M QW placebo tablet. At study conclusion, subjects completed a 34-item questionnaire. Pre-determined endpoints of preference and satisfaction were measured by asking subjects to choose the tablet, the injection, or neither, in response to questions on preference ("Which do you prefer?") and satisfaction ("With which frequency of administration have you been more satisfi ed?"). RESULTS: The subjects (n 251 ALN, n 253 DMAb) had a mean age of 67.6 years and a median length of prior bisphosphonate use of 36 months (range 6 to 192). 483 (95.8%) women took the questionnaire (240-ALN, 243-DMAb). Of the subjects who responded to the question on preference (240-ALN, 240-DMAb) or satisfaction (237-ALN, 242-DMAb), signifi cantly more subjects preferred a 6-month injection vs. a weekly oral tablet (ALN:66%-Q6M injection, 19%-QW tablet, 15%-neither, p 0.0001; DMAb:70%-Q6M injection, 19%-QW tablet, 12%-neither, p 0.0001) and signifi cantly more subjects reported greater satisfaction with the frequency of 6-month vs. weekly dosing (ALN:68%-Q6M injection, 19%-QW tablet, 14%-neither, p 0.0001; DMAb:70%-Q6M injection, 16%-QW tablet, 14%-neither, p 0.0001). CONCLUSIONS: A preference for and a greater satisfaction with a 6-month injection vs a weekly oral tablet was demonstrated in subjects previously receiving and tolerating ALN therapy.
MS2 COMBINING THE SF-36 PHYSICAL FUNCTION SCALE AND THE HEALTH ASSESSMENT QUESTIONNAIRE TO IMPROVE MEASUREMENT OF PHYSICAL FUNCTION RHEUMATOID ARTHRITIS (RA): RESULTS: FROM THE PREMIER STUDY
Hammond G 1 , Yarlas A 1 , Kosinski M 1 , Roy S 2 , Cifaldi M 2 1 QualityMetric Incorporated, Lincoln, RI, USA, 2 Abbott Laboratories, Abbott Park, IL, USA OBJECTIVES: RA clinical studies using the SF-36 Physical Function (PF) scale and Health Assessment Questionnaire (HAQ) have identifi ed limitations in each instrument's sensitivity across the full range of disease severity. Item Response Theory (IRT) estimates were used to develop a composite of both instruments (PF-HAQ) to provide a more sensitive measure of physical health. METHODS: Data for 799 patients from a 2-year randomized control study of adalimumab in early RA ( 3 years) were employed. Patients received adalimumab plus methotrexate; adalimumab monotherapy; or methotrexate monotherapy. Composite PF-HAQ scores were compared individually with PF and HAQ using 1) comparison of fl oor and ceiling effects; 2) ANCOVA models with ACR criteria classifi cation or treatment as factors (covariates: sex, age, BMI); and 3) receiver operating characteristics (ROC) analyses using ACR50 criteria as a gold standard. RESULTS: At baseline, 6.2% of patients were at fl oor for the PF. At endpoint, 37.7% and 14.2% of HAQ and PF scores, respectively, were at ceiling. IRT scores, by defi nition, have no ceiling or fl oor. Signifi cant differences across treatment groups were obtained (F [2526] 12.21, 7.48, 3.02, p 0.001 for all comparisons). PF-HAQ had signifi cantly more power than either individual scale to detect treatment differences (F-statistic ratios of PF-HAQ with PF and HAQ were 1.6 and 4.0, respectively). PF-HAQ was better than PF at detecting differences in endpoint ACR criteria (F-statistic ratio for PF-HAQ to PF was 1.28). ROC analyses indicated that PF-HAQ provided better measurement precision (p 0.001) vs. PF and equivalent/better precision vs. HAQ (p 0.14) (AUC: PF 0.80, 95% CI: 0.79-0.81; HAQ: 0.83 [0.82-0.85]; PF-HAQ: 0.84 [0.83-0.85]). CONCLUSIONS: Combining PF and HAQ measures into a single measure eliminated fl oor/ceiling effects, and provided greater effi ciency in discriminating treatment effects, as well as greater sensitivity vs. common diagnostic criteria. Clinical measures and medical resource use (number of surgeries, emergency room and physician visits, and hospitalizations within six months) were compared among three groups: patients who used biologics before but discontinued; patients who currently use biologics but skipped doses within the last 12 months; and patients who currently use biologics without skipping. Symptoms included morning stiffness, fatigue, and pain scores measured on a Likert scare from zero (no symptoms) to 10 (severe symptoms). QOL was measured by the mental component summary (MCS) and physical component summary (PCS) of the Health Survey Short Form . RESULTS: Of 2,048 respondents, 475 (23.2%) used biologic therapies, 74.3% were female, and the average age was 51.9 years. The average duration of RA was 11.9 years, with 20.0% reporting severe disease. Among patients who used biologics, 148 (31.2%) patients discontinued and 80 (16.8%) patients reported skipping doses in the last 12 months. Compared to the groups who discontinued, or skipped biologic doses, the current users who did not skip had the best symptom and QOL scores: morning stiffness (6.51, 5.91, 5.77), fatigue (7.00, 6.96, 6.23), pain (6.51, 6.18, 5.71), MCS (38.0, 41.7, 41.9), and PCS (30.4, 29.2, 32.8 ) (all P 0.05). There were no statistical differences in medical resource use except physician visits, which were signifi cantly lower in current users who did not skip doses. CONCLUSIONS: Patients who were compliant with their biologic therapy had better outcomes compared with patients who discontinued or skipped doses. Compliance with biologic therapy is an important factor optimizing effective treatment of RA.
MS3 THE IMPACT OF COMPLIANCE WITH BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS
MS4 SOCIETAL COST OF RHEUMATOID ARTHRITIS (RA) IN THE UNITED STATES: METHODOLOGY FOR INCORPORATING INTANGIBLE COSTS
Birnbaum H 1 , Pike C 1 , Kaufman R 1 , Marynchenko M 2 , Kidolezi Y 1 , Cifaldi M 3 1 Analysis Group, Inc, Boston, MA, USA, 2 Analysis Group, Inc, Montreal, QC, Canada, 3 Abbott Laboratories, Abbott Park, IL, USA OBJECTIVES: Methods have been well-established to estimate the excess amount of health care services and work loss costs of RA and, to a lesser extent, caregiver costs. To estimate the comprehensive societal cost of RA, we assessed intangible costs associated with functional disability/quality of life and mortality legal system jury award
